Skip to main content

Table 1 In vitro growth inhibitory concentrations at 50% (IC 50 ) in human cancer cells after three days of culture in the presence of the drug of interest

From: Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase

Compounds IC50(nM)
A549 U373 Hs683 T98G MCF-7 SKMEL-28 PC-3 HT-29 Mean ± SEM
Cardenolides
Ouabain* 37 ± 2 78 ± 1 34 ± 3 80 ± 3 100 ± 17 83 ± 13 63 ± 10 84 ± 8 70 ± 8
Ouabagenin* 866 ± 25 5,281 ± 250 1,902 ± 167 3,600 ± 36 4,011 ± 202 2,563 ± 183 2,708 ± 62 3,482 ± 19 3,052 ± 479
Digoxin* 60 ± 7 227 ± 42 51 ± 6 274 ± 17 363 ± 35 220 ± 26 215 ± 71 208 ± 20 202 ± 37
Digoxigenin* 395 ± 34 3,188 ± 129 794 ± 22 1,171 ± 99 5,321 ± 170 4,005 ± 116 3,880 ± 87 4,458 ± 83 2,902 ± 658
Digitoxin** 11 61 15 32 187 59 37 198 75 ± 26
Digitoxigenin** 92 369 79 166 2,134 2,495 298 230 733 ± 349
Gitoxin** 68 351 79 174 828 679 361 352 362 ± 96
Gitoxigenin** 1,715 4,477 653 3,589 5,193 > 10,000 3,964 4,403 > 4,249
Uzarigenin-rhamnoside** 45 247 38 38 469 222 77 41 147 ± 55
Uzarigenin** 3,169 7,918 2,252 5,138 > 10,000 > 10,000 6,281 6,439 > 6,025
Bufadienolides
Gamabufotalin-rhamnoside* 3 ± 1 6 ± 2 4 ± 1 7 ± 1 17 ± 5 18 ± 7 6 ± 1 8 ± 1 9 ± 2
Gamabufotalin* 7 ± 1 34 ± 1 14 ± 3 31 ± 8 40 ± 7 22 ± 1 22 ± 4 37 ± 3 26 ± 4
Hellebrin* 6 ± 1 41 ± 2 7 ± 1 30 ± 1 58 ± 12 40 ± 5 11 ± 1 27 ± 4 28 ± 7
Hellebrigenin* 3 ± 1 9 ± 1 6 ± 1 9 ± 1 42 ± 2 28 ± 9 18 ± 1 9 ± 1 16 ± 5
  1. * the data were obtained from three independent experiments, with all experiments carried out in six replicates.
  2. ** the data were obtained from one experiment carried out in six replicates.
  3. The human cancer cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA), the European Collection of Cell Culture (ECACC, Salisbury, UK), and the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). The analyzed cell lines include the A549 NSCLC (DSMZ code ACC107); the U373 (ECACC code 89081403), T98G (ATCC code CRL-1690) and Hs683 (ATCC code HTB-138) glioma; the SKMEL-28 melanoma (ATCC code HTB-72); the MCF-7 breast (DSMZ code ACC115); the PC-3 prostate (DSMZ code ACC465); and the HT-29 colon (ATCC code HTB-38) cancer models.